UCLA Geneticist Steve Horvath has led a small clinical study that effectively reversed the participant’s epigenetic clock for what appears to be about 2.5 years as reported in Nature. The study involved a combination of drugs and growth hormones. Patients were treated with a combination of growth hormone and two diabetes medications which appeared to have worked—also rejuvenating the participant’s immune systems. The participating scientists found themselves surprised by the results.
The study actually started back in 2015 when Gregory Fahy, the chief scientific officer and co-founder of Intervene Immune in Los Angeles, the study sponsor. An immunologist by profession, Fahy requested that Horvath analyze the results to assess the impact on the patients’ epigenetic clock or biological age reported Newsweek. The study went on for a year and involved nine healthy participants. They were administered a cocktail of three common drugs—growth hormone and two diabetes medications. Called the Thymus Regeneration, Immunorestoration and Insulin Mitigation (TRIIM) trial, 9 white men participated—between the ages of 51 and 65 years of age. The study was approved by the FDA in May 2015. It was conducted at Stanford Medical Center in Palo Alto, CA.
On average the participant shed 2.5 years of their biological ages, as measured by analyzing marks on a person’s genomes. Additionally, the participants’ revealed signs of immune system rejuvenation. Of course, it was a very small study and there would need to be considered more research to understand these results and the merits of this approach in human populations but nonetheless the trial results surprised the participating investigators.
Intervene Immune was founded by Greg Fahy, Ph.D. and immunologist. They are dedicated to achieving a better understanding of the fundamental biology of aging and applying this new knowledge into the practice of medicine today.
Steve Horvath, Professor of Human Genetics & Biostatistics
Call to Action: Interested in learning about actual age-reversal research, contact Intervene Immune or UCLA’s Steve Horvath. We offer links to the principals.